Treatment News

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News


February 27, 2015
Daily PrEP + ARVs in Mixed-HIV Status Couples = Prevention Success
In mixed-HIV status couples, the combination of Truvada as PrEP and antiretroviral treatment nearly eliminates transmissions.
Speed of HIV’s Replication Affects Disease Progression
The replication speed of the first strain of HIV an individual acquires has a strong correlation to the rate of immune system decline.
Ebola Outbreak Severely Compromises HIV Testing and Care
Conference on Retroviruses and Opportunistic Infections
February 26, 2015
Daclatasvir and Sovaldi Cure 97% of Hep C in Those Coinfected With HIV
Twelve weeks daclatasvir and Sovaldi offered a hep C 97 percent cure rate among those with genotypes 1 through 4 who were coinfected with HIV.
Financial Incentives Largely Fail to Improve Care for People With HIV
A large-scale program offering HIV-positive people financial incentives to get into medical care and to maintain a fully suppressed virus has failed overall.
February 25, 2015
No Progress in Testing or Treating Africans Earlier in HIV Disease
The average CD4 count of HIV-positive sub-Saharan Africans upon diagnosis or starting treatment has not risen over the past decade, indicating an overall failure to detect and treat the virus earlier in the course of HIV disease.
Attachment Inhibitor from BMS, A New Class of HIV Drug, Shows Promise
Given to treatment-experienced people with HIV, the attachment inhibitor BMS-663068 demonstrated potentcy in the range of Norvir-boosted Reyataz.
Cancer Rate is 50 Percent Higher Among People With HIV
The cancer rate of Americans diagnosed with HIV is an estimated 50 percent greater than that of the HIV-negative population.
BMS Maturation Inhibitor Is Potent Against HIV in Early Trial
Bristol-Myers Squibb’s investigatory maturation inhibitor BMS-955176 showed promise in an early trial examining its potency against HIV.
February 24, 2015
Preventing HIV in One High-Risk Person Saves up to $340,000
Researchers have estimated that preventing HIV in one high-risk individual saves an estimated $229,800 to $338,500 in lifetime medical costs.
PrEP Reduces Group of Gay Men’s Risk of HIV By 86% in UK Study
A group of British gay and bi men given Truvada as PrEP had an overall 86 percent lower risk of HIV as a consequence.
Intercourse-Based PrEP Dosing Lowers HIV Risk in Gays, But Why?
A strategy of taking Truvada as PrEP only in the days surrounding intercourse reduced the overall risk of HIV by 86 percent among gay men. However, the ongoing study has thus far failed to determine whether the dosing protocol itself was responsible for the reduction in risk, as opposed to the fact that the study participants ultimately wound up taking Truvada with some level of regularity.
Anti-HIV Vaginal Gel Study Fails Because of Poor Adherence
A trial of a Viread (tenofovir)-containing vaginal gel to protect against HIV has failed because the South African women participants used it at such low rates.
February 23, 2015
91% of HIV Passes From Those Unaware They’re Infected or Not in Care
An estimated 91.5 percent of new HIV transmits from people who do not know they are infected or who are not in medical care for the virus.
98% Hep C Cure Rate For Harvoni in Those Coinfected With HIV
Twelve weeks of Harvoni yielded a 98 percent hepatitis C cure rate among those with genotype 1 of the virus who are coinfected with HIV.
High Hep Cure Rates for Viekira Pak Among Those Coinfected With HIV
Viekira Pak plus ribavirin boasts a hepatitis C cure rate in the low-90 percent range among those with genotype 1 of the virus who are coinfected with HIV.
Critiquing UNAIDS HIV Prevention Goals, AVAC Calls For Honed Strategy
The global HIV advocacy group AVAC has raised an alarm that global goals for HIV prevention may prove ineffectual due to their vagueness.
February 20, 2015
Anti-HIV Molecule May Lead to Vaccine and Long-Acting Treatment
A new molecule blocked a simian version of HIV from attaching to immune cells, and may work as both a long-acting treatment and a vaccine for HIV in humans.
February 19, 2015
PrEP Users’ Sexually Acquired Hep C Suggests Need for Routine Testing
Evidence of sexual acquisition of hepatitis C among gay men receiving PrEP at a San Francisco clinic has prompted a call for routine testing for the virus among PrEP users.
February 18, 2015
African-American HIV Conspiracy Theories Derive From Mistrust
African Americans who believe conspiracy theories that HIV was created by the government to kill off blacks are motivated by distrust of the government.
February 17, 2015
An Aggressive Form of HIV Appears to Have Surfaced in Cuba
Researchers believe they have found an aggressive strain of HIV among Cubans that progresses to AIDS in just three years, instead of the typical 10.
February 13, 2015
Daily Antibiotic May Work as PrEP Against STIs Other Than HIV
A daily dose of the antibiotic doxycycline may be effective as pre-exposure prophylaxis (PrEP) against gonorrhea, chlamydia and syphilis.
February 12, 2015
Kidneys From Donors With HIV Transplant Well Into HIV-Positive Recipients
People with HIV can successfully receive transplanted kidneys from HIV-positive donors.
February 11, 2015
HIV and Syphilis Smartphone Assay Would Aid Testing in Remote Areas
Researchers have developed a low-cost smartphone accessory that can conduct a 15-minute test for HIV and syphilis with only a finger prick.
February 10, 2015
Death Rates Among HIV-Positive People, Especially Blacks, Are Falling
The death rate of HIV-positive African Americans has declined considerably in recent years, although significant disparities still exist when the statistics are compared with those of whites and Latinos,
February 09, 2015
A Call for Improved HIV-Related Scientific Literacy on the Front Lines
Poor scientific literacy among non-medical members of the HIV-related workforce must be addressed in order to better fight the epidemic.
February 05, 2015
Failed VOICE PrEP Trial Failed to Preempt Lies About Adherence
The failure of the VOICE trial of oral and vaginal gel PrEP was the result of low adherence among the sub-Saharan African women participants, many of whom actively lied about their adherence.
February 04, 2015
New Guidelines for Bone Care Among People With HIV
An international panel has released new guidelines on the management of bone density decline among people with HIV.
February 03, 2015
Craigslist Personals’ Intro Into Local Markets Linked to 16% Rise in HIV
When Craigslist introduced its personal section into respective areas around the country, the arrival was linked to a 15.9 percent risk in HIV incidence.
February 02, 2015
Early HIV Treatment Advantage Is Lost If Treatment Is Interrupted
The immune recovery benefits conferred by starting antiretrovirals for HIV shortly after infection are lost if treatment is later interrupted.
HIV Viral Rebounds Predict Fibrosis in HCV-Coinfected People
People coinfected with HIV and hepatitis C are more likely to develop liver fibrosis if they experience an HIV viral load rebound, rather than just a blip.
More Treatment News

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ



Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Does your insurance company put HIV meds on its priciest tier?
Yes
No

Survey
Lean On Me

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2015 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.